China has approved the first phase of human trials for a potential COVID-19 vaccine administered via nasal spray.
According to Bloomberg News, Incoming is being developed by Xiamen University, University of Hong Kong and vaccine manufacturer Beijing Wekai Biological Pharmacy Enterprise.
It is the 10th such candidate from China to advance to the critical stage of human testing.
WHO SCIENTIST SAYS ASTRAZENECA CORONAVIRUS TRIAL PAUSE IS ‘GOOD WAKE-UP CALL’
The spray contains weak flu virus strains with genetic segments of coronovirus spike proteins. Once in the body, it mimics the natural infection of the respiratory virus, which encourages the body’s immune response against the pathogen that causes COVID-19, Science and Technology Daily reports. The paper is affiliated with the Ministry of Science and Technology of China.
The expectation is that the vaccine sprayed through the nose may have a better chance of stopping the virus in the respiratory tract, while a shot may not be strong enough to prevent infection.
Reinforced the concept by encouraging animal-based tests.
A study published last month by researchers at Washington University School of Medicine in St. Louis concluded that a nasal vaccine prevents infection in mice – significantly reducing lung damage – and that the spray sprays virus away Was more successful.
Intranasal sprays are already employed to prevent the flu and the US Center for Disease Control and Prevention has highlighted their usefulness.
The World Health Organization reports that at least 35 coronavirus vaccine trials are currently underway worldwide.
A major study conducted by the pharmaceutical company AstraZeneca and the University of Oxford, however, halted this week after researchers reported a participant reported “possibly unexplained illness”.
In the wake of AstraZeneca’s return, China’s own developers – Cancino Biologics Inc. and state-owned China’s National Biotech Group Company have assured consumers about the safety of their shots.
Click here for the Fox News app
None of the Chinese diplomats who traveled to the virus’s hot spots abroad after receiving CNBG vaccines have reported months of infection, their general counsel told the Science and Technology Daily.
According to Marketwatch, there are seven vaccine candidates who have gone into clinical trials with human participants, including three who have gone through a critical stage phase.